Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas.

Next Previous
Search
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 565 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors MedImmune; Micromet Inc

Most Recent Events

  • 02 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 29 Sep 2014 Planned number of patients changed from 115 to 99 as reported by ClinicalTrials.gov.
  • 02 Apr 2014 Planned end date changed from 1 Oct 2017 to 1 Aug 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top